1983
DOI: 10.1016/0002-9343(83)91174-9
|View full text |Cite
|
Sign up to set email alerts
|

Lymphosarcoma cell leukemia and other non-Hodgkin's lymphomas in leukemic phase

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
3
0

Year Published

1984
1984
2012
2012

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 16 publications
(3 citation statements)
references
References 72 publications
0
3
0
Order By: Relevance
“…The presence of circulating malignant lymphoma cells in the blood is well‐recognized in mantle cell lymphoma, follicular lymphoma, anaplastic large cell lymphoma, and in terminal phases of all refractory lymphomas (Morra et al , ; Berinstein et al , ; Criel et al , ; Villamor et al , ). Clinical and pathological description of DLBCL presenting with circulating lymphoma cells or in ‘leukaemic phase’ has been previously reported as a subgroup of the lymphosarcoma cell leukaemia (Schwartz et al , ; Mintzer & Hauptman, ) and only in small cohorts focusing primarily on the pathological findings (Come et al , ). We herein report the clinical characteristics, response to treatment and outcomes of 29 patients with DLBCL presenting in leukaemic phase at two institutions.…”
mentioning
confidence: 99%
“…The presence of circulating malignant lymphoma cells in the blood is well‐recognized in mantle cell lymphoma, follicular lymphoma, anaplastic large cell lymphoma, and in terminal phases of all refractory lymphomas (Morra et al , ; Berinstein et al , ; Criel et al , ; Villamor et al , ). Clinical and pathological description of DLBCL presenting with circulating lymphoma cells or in ‘leukaemic phase’ has been previously reported as a subgroup of the lymphosarcoma cell leukaemia (Schwartz et al , ; Mintzer & Hauptman, ) and only in small cohorts focusing primarily on the pathological findings (Come et al , ). We herein report the clinical characteristics, response to treatment and outcomes of 29 patients with DLBCL presenting in leukaemic phase at two institutions.…”
mentioning
confidence: 99%
“…Survival is often less than two months [3,4]. Although the majority of patients succumb to disseminated visceral disease, a small but distinct minority will develop central nervous system complications secondary to direct involvement by lymphoma.…”
Section: Discussionmentioning
confidence: 99%
“…Patients in these subsets have a much worse prognosis than do those with B-CLL, as evidenced by the clinical course of our 11 patients with small cleaved cell leukemia and those described in other studies. 18,19 Both of these subsets are usually associated with strong slg expression. The clinical relevance of strong slg expression in the context of B-CLL (that is, in the absence of circulating prolymphocytes or small cleaved cells) has not been described pre viously.…”
Section: Discussionmentioning
confidence: 99%